Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7 pseudogene 54 (RPL7P54) is a processed pseudogene in the human genome that is related to the canonical ribosomal protein L7 gene (RPL7). Unlike the functional RPL7 gene, which codes for an essential protein component of the 60S large ribosomal subunit, RPL7P54 does not produce a functional protein product and is classified as a non-coding pseudogene[7][8]. Pseudogenes like RPL7P54 are considered genomic “fossils” created from gene duplication or retrotransposition events; they typically lack regulatory elements for gene expression, or contain disabling mutations that prevent functional protein synthesis[10][11]. RPL7P54 has no direct involvement as a molecular target for therapeutics, no established function in human biology, and is not associated with pathological processes or drug response[7][8]. There is no evidence or indication that this specific pseudogene is misspelled, mischaracterized, or otherwise incorrect or non-unique. Supporting details: RPL7P54 is specifically annotated as a pseudogene, meaning it does not encode a functional protein product[7][8]. As with most ribosomal protein pseudogenes, there are no described biological functions, drug interactions, or disease involvements[7][8][10][11]. Pseudogenes are not considered protein or receptor targets and do not belong to standard molecular target classes such as enzyme, receptor, transporter, etc.[7][8][10]. Summary: RPL7P54 is a non-functional processed pseudogene derived from the ribosomal protein L7 gene, does not encode a protein, has no biological function, and is not a therapeutic target[7][8][10][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 54 (RPL7P54).